GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qyuns Therapeutics Co Ltd (HKSE:02509) » Definitions » Current Accrued Expense

Qyuns Therapeutics Co (HKSE:02509) Current Accrued Expense : HK$0.0 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Qyuns Therapeutics Co Current Accrued Expense?

Qyuns Therapeutics Co's Current Accrued Expense for the quarter that ended in Dec. 2024 was HK$0.0 Mil.


Qyuns Therapeutics Co Current Accrued Expense Historical Data

The historical data trend for Qyuns Therapeutics Co's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qyuns Therapeutics Co Current Accrued Expense Chart

Qyuns Therapeutics Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Current Accrued Expense
- - - -

Qyuns Therapeutics Co Quarterly Data
Dec21 Dec22 Sep23 Dec23 Jun24 Dec24
Current Accrued Expense Get a 7-Day Free Trial - - - - -

Qyuns Therapeutics Co Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Qyuns Therapeutics Co Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Qyuns Therapeutics Co's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Qyuns Therapeutics Co Business Description

Traded in Other Exchanges
N/A
Address
No. 907 Yaocheng Avenue, Room 1310, Building 1, Taizhou, Jiangsu, CHN
Qyuns Therapeutics Co Ltd is a a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory and digestive diseases Key revenue is generated from PRC.
Executives
Tai Zhou Yi Yao Cheng Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Tai Zhou Jian Xin Chuang Ye Tou Zi You Xian Gong Si 2101 Beneficial owner
Hang Zhou Zhong Mei Hua Dong Zhi Yao You Xian Gong Si 2101 Beneficial owner
Zhong Guo Yuan Da Ji Tuan You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you
Tai Zhou Yi Yao Gao Xin Ji Shu Chan Ye Tou Zi Fa Zhan You Xian Gong Si 2201 Interest of corporation controlled by you
Tai Zhou Yi Yao Gao Xin Qu Hua Yin Jin Rong Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Yuan Da Hua Chuang Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Hua Dong Yi Yao Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Qiu Jiwan
Xu Qiu
Hangzhou Quanyi Investment Management Partnership (general Partnership)
Yu Guo'an
Zhu Jing
Taizhou Xinfu Tongxin Enterprise Management Partnership (limited Partnership)
Sheng Xi Tai

Qyuns Therapeutics Co Headlines

No Headlines